MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Prostate Cancer Treatment and Research
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

3,880 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
3,880 works in the cohort · of 4,299,418page 55 of 78

Labels cover 13 of 3,880 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 3,880 of 3,880 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
Editorial: The development of lethal prostate cancer
Baotong Zhang, Sifeng Qu, Xin Li, Xinpei Ci, Chang Jiang
2023· editorial· en· Frontiers in Cell and Developmental Biology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affvenueunlabeled
SIU-ICUD: Localized Prostate Cancer
Laurence Klotz
2025· article· en· Société Internationale d’Urologie Journal· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affunlabeled
Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study.
Vincenzo Gennusa, Calogero Saieva, Richard M. Lee‐Ying, Pier Vitale Nuzzo, Gian Paolo Spinelli, Elisa Zanardi +13 more
2023· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affvenueaboutunlabeled
Urological outcomes in nonagenarians with prostate cancer
Joshua White, Jesse Ory, Heather Morris, Ricardo Rendon, Ross Mason, Ashley Cox
2021· article· en· Canadian Urological Association Journal· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
587P Clinical and cost impact of cabazitaxel versus (vs) a second androgen receptor targeted agent (ARTA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and the alternative ARTA (abiraterone or enzalutamide)
Alicia K. Morgans, Thomas E. Hutson, Alice Guan, David Garcia, Anna Zhou, Edward J. Drea +1 more
2021· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
aboutno affunlabeled
MP61-01 FUNCTIONAL ROLE OF THE KALLIKREIN 6 REGION OF THE KALLIKREIN LOCUS IN GENETIC PREDISPOSITION FOR AGGRESSIVE (GLEASON ≥8) PROSTATE CANCER: FINE-MAPPING AND METHYLATION STUDY IN A CANADIAN COHORT AND THE SWISS ARM OF THE EUROPEAN RANDOMIZED STUDY FOR PROSTATE CANCER SCREENING
Laurent Briollais, Hilmi Özçelik, Maciej Kwiatkowski, Jingxiong Xu, Sevtap Savas, Ekaterina Olkhov‐Mitsel +14 more
2015· article· en· The Journal of Urology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affunlabeled
Novel imaging in advanced prostate cancer
Hanan Goldberg, Robert J. Hamilton
2017· review· en· Current Opinion in Supportive and Palliative Care· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affunlabeled
Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database.
Edoardo Francini, Francesca Montagnani, Pier Vitale Nuzzo, Miguel González-Vélez, Nimira Alimohamed, Antonio Cigliola +14 more
2020· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations

How this was built: Screen · Findings · About